| 1 | Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapy | 1.4 | 12 | Citations (PDF) |
| 2 | Predictors for choosing doravirine‐based versus INSTI‐based regimen in ART‐naïve and ART‐experienced people with HIV in real‐world setting: Data from the Icona cohort | 1.8 | 1 | Citations (PDF) |
| 3 | HIV and hospitals between knowledge and stigma | 0.9 | 1 | Citations (PDF) |
| 4 | Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort | 1.8 | 3 | Citations (PDF) |
| 5 | Bridging the evidence gap: expert consensus on management of SARS-CoV-2 acute infection and post–COVID-19 condition in immunocompromised patients | 3.5 | 0 | Citations (PDF) |
| 6 | Influence of efavirenz and 8‐hydroxy‐efavirenz plasma levels on cognition and central nervous system side effects | 1.8 | 4 | Citations (PDF) |
| 7 | Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts | 1.8 | 48 | Citations (PDF) |
| 8 | Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort | 1.9 | 4 | Citations (PDF) |
| 9 | Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition | 1.1 | 7 | Citations (PDF) |
| 10 | Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy | 1.8 | 4 | Citations (PDF) |
| 11 | Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy | 2.0 | 17 | Citations (PDF) |
| 12 | HIV‐NAAT use for early detection of HIV infection among high‐risk men who have sex with men in Italy | 1.8 | 1 | Citations (PDF) |
| 13 | Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures | 1.9 | 7 | Citations (PDF) |
| 14 | Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19 | 3.5 | 4 | Citations (PDF) |
| 15 | Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study) | 6.6 | 7 | Citations (PDF) |
| 16 | HIV-Indicator Condition Guided Testing in a Hospital Setting | 1.9 | 8 | Citations (PDF) |
| 17 | Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infectionAids, 2023, 37, 1503-1517 | 1.5 | 12 | Citations (PDF) |
| 18 | Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study–authors’ response | 2.1 | 1 | Citations (PDF) |
| 19 | Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV | 2.7 | 19 | Citations (PDF) |
| 20 | Impact of COVID Pandemic on Sexual Habits and Pre-exposure Prophylaxis Retention in Care in a Community-Based Service | 0.9 | 2 | Citations (PDF) |
| 21 | Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort | 3.1 | 3 | Citations (PDF) |
| 22 | SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio | 1.9 | 19 | Citations (PDF) |
| 23 | Risk Awareness as a Key Determinant of Early Vaccine Uptake in the Mpox Vaccination Campaign in an Italian Region: A Cross-Sectional Analysis | 1.9 | 6 | Citations (PDF) |
| 24 | Female gender is associated with long COVID syndrome: a prospective cohort study | 3.5 | 543 | Citations (PDF) |
| 25 | Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy | 1.8 | 4 | Citations (PDF) |
| 26 | Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects | 0.7 | 12 | Citations (PDF) |
| 27 | Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting | 0.7 | 5 | Citations (PDF) |
| 28 | One‐year cognitive follow‐up of COVID‐19 hospitalized patients | 2.4 | 113 | Citations (PDF) |
| 29 | Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy – The CHILI study | 1.9 | 12 | Citations (PDF) |
| 30 | Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19 | 1.9 | 6 | Citations (PDF) |
| 31 | Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process | 1.8 | 5 | Citations (PDF) |
| 32 | Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium | 5.9 | 139 | Citations (PDF) |
| 33 | Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors | 3.3 | 25 | Citations (PDF) |
| 34 | Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects | 2.2 | 2 | Citations (PDF) |
| 35 | Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease | 2.5 | 12 | Citations (PDF) |
| 36 | Management of Chronic Hepatitis B in HIV-Coinfected Patients | 2.2 | 11 | Citations (PDF) |
| 37 | Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19 | 2.5 | 10 | Citations (PDF) |
| 38 | Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE | 3.7 | 17 | Citations (PDF) |
| 39 | The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study | 2.2 | 7 | Citations (PDF) |
| 40 | Dyslipidaemia after switch to tenofovir alafenamide (TAF)‐based cART regimens in a cohort of HIV‐positive patients: what clinical relevance? | 1.8 | 19 | Citations (PDF) |
| 41 | Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy | 2.0 | 144 | Citations (PDF) |
| 42 | The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy | 1.8 | 20 | Citations (PDF) |
| 43 | Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U eraAids, 2021, 35, 1103-1112 | 1.5 | 23 | Citations (PDF) |
| 44 | Long-Lasting Cognitive Abnormalities after COVID-19 | 1.8 | 171 | Citations (PDF) |
| 45 | Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes | 3.3 | 39 | Citations (PDF) |
| 46 | Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States | 2.2 | 9 | Citations (PDF) |
| 47 | Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study | 1.2 | 24 | Citations (PDF) |
| 48 | Prevalence and outcomes of pregnancies in women with HIV over a 20-year periodAids, 2021, 35, 2025-2033 | 1.5 | 9 | Citations (PDF) |
| 49 | Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss | 2.7 | 11 | Citations (PDF) |
| 50 | Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers | 6.6 | 26 | Citations (PDF) |
| 51 | The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-seriesAids, 2021, 35, 2341-2346 | 1.5 | 24 | Citations (PDF) |
| 52 | Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV | 1.7 | 7 | Citations (PDF) |
| 53 | Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy | 7.3 | 23 | Citations (PDF) |
| 54 | A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy | 1.8 | 1 | Citations (PDF) |
| 55 | Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy | 1.8 | 5 | Citations (PDF) |
| 56 | Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study | 2.2 | 10 | Citations (PDF) |
| 57 | Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study | 3.1 | 9 | Citations (PDF) |
| 58 | HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review | 3.2 | 63 | Citations (PDF) |
| 59 | JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy | 1.8 | 8 | Citations (PDF) |
| 60 | Declining Mortality Rate of Hospitalised Patients in the Second Wave of the COVID-19 Epidemics in Italy: Risk Factors and the Age-Specific Patterns | 1.9 | 11 | Citations (PDF) |
| 61 | Resilience, Psychological Well-Being and Daily Functioning Following Hospitalization for Respiratory Distress Due to SARS-CoV-2 Infection | 1.6 | 6 | Citations (PDF) |
| 62 | Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy | 2.4 | 5 | Citations (PDF) |
| 63 | Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort | 1.2 | 4 | Citations (PDF) |
| 64 | Predictors of low ovarian reserve in cART-treated women living with HIV | 1.0 | 11 | Citations (PDF) |
| 65 | Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus | 3.7 | 21 | Citations (PDF) |
| 66 | Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect | 1.3 | 5 | Citations (PDF) |
| 67 | Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice | 1.7 | 10 | Citations (PDF) |
| 68 | HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients | 0.7 | 5 | Citations (PDF) |
| 69 | Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia | 2.7 | 50 | Citations (PDF) |
| 70 | Chest pain and a left parasternal soft tissue swelling in an immunocompetent refugee with disseminated tuberculosis | 1.4 | 3 | Citations (PDF) |
| 71 | The EuroSIDA study: 25 years of scientific achievements | 1.8 | 32 | Citations (PDF) |
| 72 | Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort | 2.1 | 8 | Citations (PDF) |
| 73 | Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles? | 0.7 | 16 | Citations (PDF) |
| 74 | Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry | 0.7 | 42 | Citations (PDF) |
| 75 | Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings | 2.2 | 14 | Citations (PDF) |
| 76 | The importance of patients’ case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease | 1.4 | 15 | Citations (PDF) |
| 77 | Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study | 1.7 | 4 | Citations (PDF) |
| 78 | Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy | 2.2 | 14 | Citations (PDF) |
| 79 | Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal? | 1.4 | 11 | Citations (PDF) |
| 80 | Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness | 3.3 | 54 | Citations (PDF) |
| 81 | What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts | 1.8 | 25 | Citations (PDF) |
| 82 | Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice | 1.4 | 4 | Citations (PDF) |
| 83 | Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study) | 2.4 | 36 | Citations (PDF) |
| 84 | Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts | 2.0 | 2 | Citations (PDF) |
| 85 | Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies | 2.8 | 26 | Citations (PDF) |
| 86 | Compassionate Use of Remdesivir for Patients with Severe Covid-19 | 26.4 | 2,411 | Citations (PDF) |
| 87 | Ability to Monitor National Responses to the HIV Epidemic “Beyond Viral Suppression”: Findings From Six European Countries | 1.8 | 4 | Citations (PDF) |
| 88 | Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium | 1.5 | 10 | Citations (PDF) |
| 89 | Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study | 3.7 | 23 | Citations (PDF) |
| 90 | Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015 | 1.5 | 50 | Citations (PDF) |
| 91 | Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study | 2.2 | 16 | Citations (PDF) |
| 92 | Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients | 0.7 | 31 | Citations (PDF) |
| 93 | Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets | 1.7 | 15 | Citations (PDF) |
| 94 | Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? | 2.1 | 5 | Citations (PDF) |
| 95 | Association Between Impaired Vα7.2+CD161++CD8+ (MAIT) and Vα7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients | 2.9 | 27 | Citations (PDF) |
| 96 | Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort | 2.1 | 16 | Citations (PDF) |
| 97 | Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study | 1.6 | 4 | Citations (PDF) |
| 98 | Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study | 6.6 | 17 | Citations (PDF) |
| 99 | Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort | 2.2 | 61 | Citations (PDF) |
| 100 | Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting | 2.1 | 22 | Citations (PDF) |
| 101 | Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study | 1.9 | 5 | Citations (PDF) |
| 102 | Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL | 2.1 | 14 | Citations (PDF) |
| 103 | Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen | 1.9 | 7 | Citations (PDF) |
| 104 | Is the rate of virological failure to cART continuing to decline in recent calendar years? | 2.2 | 12 | Citations (PDF) |
| 105 | Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression | 1.5 | 1 | Citations (PDF) |
| 106 | Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities | 1.5 | 23 | Citations (PDF) |
| 107 | Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis | 3.2 | 38 | Citations (PDF) |
| 108 | Reorienting health systems to care for people with HIV beyond viral suppression | 5.9 | 88 | Citations (PDF) |
| 109 | Serious clinical events in HIV-positive persons with chronic kidney diseaseAids, 2019, 33, 2173-2188 | 1.5 | 14 | Citations (PDF) |
| 110 | Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy | 1.2 | 40 | Citations (PDF) |
| 111 | Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials | 46.9 | 371 | Citations (PDF) |
| 112 | Health system capacity to report on indicators fostering integrated
people-centred HIV care: findings from six European countries | 0.2 | 1 | Citations (PDF) |
| 113 | Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort | 2.0 | 6 | Citations (PDF) |
| 114 | Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma | 3.2 | 21 | Citations (PDF) |
| 115 | Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study | 1.9 | 2 | Citations (PDF) |
| 116 | Immune Activation, Inflammation and HIV DNA after 96 Weeks of ATV/r Monotherapy: A MODAt Substudy | 1.9 | 2 | Citations (PDF) |
| 117 | Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study | 4.4 | 26 | Citations (PDF) |
| 118 | Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy | 2.1 | 24 | Citations (PDF) |
| 119 | Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature | 1.7 | 5 | Citations (PDF) |
| 120 | Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+Aids, 2018, 32, 1361-1367 | 1.5 | 22 | Citations (PDF) |
| 121 | HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients | 1.5 | 6 | Citations (PDF) |
| 122 | Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients | 1.5 | 6 | Citations (PDF) |
| 123 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program | 3.7 | 8 | Citations (PDF) |
| 124 | Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord | 2.8 | 25 | Citations (PDF) |
| 125 | Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990–2014 | 6.7 | 63 | Citations (PDF) |
| 126 | Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort | 1.2 | 18 | Citations (PDF) |
| 127 | Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies | 5.9 | 1,009 | Citations (PDF) |
| 128 | Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study | 3.7 | 57 | Citations (PDF) |
| 129 | The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges | 3.7 | 51 | Citations (PDF) |
| 130 | Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients | 1.5 | 7 | Citations (PDF) |
| 131 | Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression | 1.2 | 2 | Citations (PDF) |
| 132 | Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation | 2.1 | 7 | Citations (PDF) |
| 133 | CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC) | 3.7 | 92 | Citations (PDF) |
| 134 | Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV | 1.2 | 5 | Citations (PDF) |
| 135 | SP364IRON CITRATE INHIBITS PHOSPHATE-INDUCED EARLY APOPTOSIS BY PREVENTING PHOSPHATIDYLSERINE TRANSLOCATION AND MITOCHONDRIAL DEPOLARIZATION | 0.7 | 0 | Citations (PDF) |
| 136 | Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens | 1.5 | 15 | Citations (PDF) |
| 137 | Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population | 1.5 | 40 | Citations (PDF) |
| 138 | Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort | 1.5 | 16 | Citations (PDF) |
| 139 | Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study | 1.5 | 72 | Citations (PDF) |
| 140 | Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study | 4.6 | 26 | Citations (PDF) |
| 141 | CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus | 2.1 | 7 | Citations (PDF) |
| 142 | SP373IRON CITRATE PREVENTS PHOSPHATE INHIBITION OF RANKL-INDUCED OSTEOCLASTIC DIFFERENTIATION IN HUMAN MONOCYTE CELLS | 0.7 | 0 | Citations (PDF) |
| 143 | Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial | 1.5 | 12 | Citations (PDF) |
| 144 | Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort | 1.5 | 5 | Citations (PDF) |
| 145 | T-Cell Phenotype and Function following a First cART Regimen Containing Either a Protease Inhibitor or a Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Late Presenters: Results from a Retrospective,
ex vivo
Study | 1.9 | 5 | Citations (PDF) |
| 146 | Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy | 3.3 | 34 | Citations (PDF) |
| 147 | Illness Representations of HIV Positive Patients Are Associated with Virologic Success | 1.6 | 8 | Citations (PDF) |
| 148 | Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive personsAids, 2016, 30, 1731-1743 | 1.5 | 58 | Citations (PDF) |
| 149 | Discontinuation of Initial Antiretroviral Therapy in Clinical Practice | 1.2 | 40 | Citations (PDF) |
| 150 | Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?Aids, 2016, 30, 1629-1637 | 1.5 | 9 | Citations (PDF) |
| 151 | Improvements over time in short-term mortality following myocardial infarction in HIV-positive individualsAids, 2016, 30, 1583-1596 | 1.5 | 10 | Citations (PDF) |
| 152 | Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study | 0.7 | 24 | Citations (PDF) |
| 153 | Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study | 2.0 | 0 | Citations (PDF) |
| 154 | Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus–Related Anal Dysplastic Lesions | 3.7 | 1 | Citations (PDF) |
| 155 | The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro | 1.9 | 4 | Citations (PDF) |
| 156 | Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study | 9.2 | 166 | Citations (PDF) |
| 157 | Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study | 1.9 | 26 | Citations (PDF) |
| 158 | High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects | 1.0 | 4 | Citations (PDF) |
| 159 | Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy | 1.5 | 75 | Citations (PDF) |
| 160 | Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART | 2.1 | 13 | Citations (PDF) |
| 161 | Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial | 2.1 | 8 | Citations (PDF) |
| 162 | Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen | 2.1 | 4 | Citations (PDF) |
| 163 | Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study | 5.9 | 182 | Citations (PDF) |
| 164 | Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy | 2.8 | 62 | Citations (PDF) |
| 165 | An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study | 1.5 | 225 | Citations (PDF) |
| 166 | Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern | 2.1 | 52 | Citations (PDF) |
| 167 | Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy | 1.5 | 110 | Citations (PDF) |
| 168 | Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice | 1.5 | 5 | Citations (PDF) |
| 169 | Affronto multidisciplinare delle co-morbiditità HIV-correlate: esperienza e casistica di un centro italiano | 0.0 | 0 | Citations (PDF) |
| 170 | Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort | 1.5 | 0 | Citations (PDF) |
| 171 | Reply to Manfredi | 2.2 | 0 | Citations (PDF) |
| 172 | Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals | 1.2 | 44 | Citations (PDF) |
| 173 | Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy | 1.5 | 9 | Citations (PDF) |
| 174 | Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus | 1.5 | 7 | Citations (PDF) |
| 175 | Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing | 2.1 | 115 | Citations (PDF) |
| 176 | CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study | 5.9 | 300 | Citations (PDF) |
| 177 | Immunophenotype and Function of CD38-Expressing CD4+ and CD8+ T Cells in HIV-Infected Patients Undergoing Suppressive Combination Antiretroviral Therapy | 2.2 | 16 | Citations (PDF) |
| 178 | Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? | 3.1 | 34 | Citations (PDF) |
| 179 | Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients | 2.2 | 180 | Citations (PDF) |
| 180 | Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013 | 3.4 | 78 | Citations (PDF) |
| 181 | Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries | 1.2 | 150 | Citations (PDF) |
| 182 | Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC) | 2.8 | 71 | Citations (PDF) |
| 183 | Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure | 2.1 | 6 | Citations (PDF) |
| 184 | Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women | 1.2 | 6 | Citations (PDF) |
| 185 | Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppressionAids, 2014, 28, 2269-2279 | 1.5 | 22 | Citations (PDF) |
| 186 | Delayed HIV diagnosis and initiation of antiretroviral therapyAids, 2014, 28, 2297-2306 | 1.5 | 42 | Citations (PDF) |
| 187 | Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study | 1.7 | 26 | Citations (PDF) |
| 188 | Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience | 2.0 | 13 | Citations (PDF) |
| 189 | Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration | 46.9 | 866 | Citations (PDF) |
| 190 | Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery | 3.7 | 174 | Citations (PDF) |
| 191 | Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients | 3.7 | 154 | Citations (PDF) |
| 192 | Life Expectancy in the Immune Recovery Era | 1.2 | 25 | Citations (PDF) |
| 193 | Deteriorating renal function and clinical outcomes in HIV-positive persons | 1.5 | 31 | Citations (PDF) |
| 194 | Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment | 1.5 | 6 | Citations (PDF) |
| 195 | Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients | 4.8 | 50 | Citations (PDF) |
| 196 | The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study | 1.7 | 57 | Citations (PDF) |
| 197 | Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? | 6.7 | 42 | Citations (PDF) |
| 198 | Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events | 1.5 | 94 | Citations (PDF) |
| 199 | Insurability of HIV-positive people treated with antiretroviral therapy in EuropeAids, 2013, 27, 1641-1655 | 1.5 | 11 | Citations (PDF) |
| 200 | Associations between immune depression and cardiovascular events in HIV infectionAids, 2013, 27, 2735-2748 | 1.5 | 57 | Citations (PDF) |
| 201 | CD8 T-Cell Activation Is Associated With Lipodystrophy and Visceral Fat Accumulation in Antiretroviral Therapy–Treated Virologically Suppressed HIV-Infected Patients | 1.2 | 22 | Citations (PDF) |
| 202 | Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) | 4.6 | 297 | Citations (PDF) |
| 203 | Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes | 2.2 | 7 | Citations (PDF) |
| 204 | The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era | 3.7 | 100 | Citations (PDF) |
| 205 | Risk of tuberculosis following HIV seroconversion in high-income countries | 3.4 | 27 | Citations (PDF) |
| 206 | Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen | 2.1 | 8 | Citations (PDF) |
| 207 | Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts | 3.7 | 101 | Citations (PDF) |
| 208 | Free Light Chains and the Risk of Nonmalignant AIDS Events in HIV-Infected Patients Treated With Combination Antiretroviral Therapy | 3.7 | 3 | Citations (PDF) |
| 209 | The Need for Data on Women Living with HIV in Europe | 1.9 | 4 | Citations (PDF) |
| 210 | What Do We Know about Antiretroviral Treatment of HIV in Women? | 1.9 | 19 | Citations (PDF) |
| 211 | Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment | 1.5 | 81 | Citations (PDF) |
| 212 | Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients | 1.2 | 16 | Citations (PDF) |
| 213 | Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study | 1.7 | 72 | Citations (PDF) |
| 214 | Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) | 1.5 | 182 | Citations (PDF) |
| 215 | Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition | 3.7 | 29 | Citations (PDF) |
| 216 | Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics | 2.8 | 37 | Citations (PDF) |
| 217 | All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration | 2.8 | 238 | Citations (PDF) |
| 218 | Exposure to Abacavir and Biomarkers of Cardiovascular Disease in HIV-1–Infected Patients on Suppressive Antiretroviral Therapy | 1.2 | 6 | Citations (PDF) |
| 219 | Prevalence of Prolonged Amenorrhea in HIV-Infected Women | 1.2 | 6 | Citations (PDF) |
| 220 | Long-term exposure to combination antiretroviral therapy and risk of death from specific causes | 1.5 | 35 | Citations (PDF) |
| 221 | The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression | 1.9 | 10 | Citations (PDF) |
| 222 | T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis | 1.5 | 69 | Citations (PDF) |
| 223 | Predicting the short‐term risk of diabetes in HIV‐positive patients: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study | 2.2 | 64 | Citations (PDF) |
| 224 | Role of serum free light chains in predicting HIV‐associated non‐Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy | 5.2 | 26 | Citations (PDF) |
| 225 | Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis | 1.6 | 0 | Citations (PDF) |
| 226 | Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients | 1.5 | 35 | Citations (PDF) |
| 227 | Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis | 1.5 | 17 | Citations (PDF) |
| 228 | Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients | 0.2 | 4 | Citations (PDF) |
| 229 | Elevated triglycerides and risk of myocardial infarction in HIV-positive personsAids, 2011, 25, 1497-1504 | 1.5 | 43 | Citations (PDF) |
| 230 | Hepatitis delta in HIV-infected individuals in EuropeAids, 2011, 25, 1987-1992 | 1.5 | 85 | Citations (PDF) |
| 231 | Comparative Effectiveness of Initial Antiretroviral Therapy Regimens | 1.2 | 20 | Citations (PDF) |
| 232 | The Coding Causes of Death in HIV (CoDe) Project | 2.0 | 144 | Citations (PDF) |
| 233 | Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell countAids, 2011, 25, 1385-1394 | 1.5 | 167 | Citations (PDF) |
| 234 | Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome | 1.9 | 53 | Citations (PDF) |
| 235 | Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI | 1.7 | 6 | Citations (PDF) |
| 236 | Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy | 1.5 | 105 | Citations (PDF) |
| 237 | Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients | 0.2 | 1 | Citations (PDF) |
| 238 | High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome | 1.5 | 82 | Citations (PDF) |
| 239 | Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapyAids, 2010, 24, 2590-2593 | 1.5 | 21 | Citations (PDF) |
| 240 | Is There Any Potential for First-Line Etravirine Use? Analysis From a Large Data Set of Antiretroviral Therapy-Naive HIV-Infected Patients Undergoing Resistance Test | 1.2 | 0 | Citations (PDF) |
| 241 | Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D studyAids, 2010, 24, 1537-1548 | 1.5 | 401 | Citations (PDF) |
| 242 | HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study | 1.9 | 38 | Citations (PDF) |
| 243 | Predicting the magnitude of short-term CD4
+
T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy | 1.9 | 16 | Citations (PDF) |
| 244 | Medical and Societal Consequences of Late Presentation | 1.9 | 63 | Citations (PDF) |
| 245 | Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAARTAids, 2010, 24, 1455-1460 | 1.5 | 37 | Citations (PDF) |
| 246 | Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies | 2.7 | 125 | Citations (PDF) |
| 247 | Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy | 1.5 | 19 | Citations (PDF) |
| 248 | Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study | 2.2 | 615 | Citations (PDF) |
| 249 | Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe | 2.1 | 55 | Citations (PDF) |
| 250 | Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study | 2.2 | 337 | Citations (PDF) |
| 251 | Noninfectious HIV-Related Comorbidities and Haart Toxicities: Choosing Alternative Antiretroviral Strategies | 0.5 | 4 | Citations (PDF) |
| 252 | Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors | 2.1 | 59 | Citations (PDF) |
| 253 | Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource‐Limited Settings | 2.2 | 56 | Citations (PDF) |
| 254 | Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients | 1.2 | 23 | Citations (PDF) |
| 255 | Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries | 2.8 | 179 | Citations (PDF) |
| 256 | Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals | 5.6 | 34 | Citations (PDF) |
| 257 | Risk of Developing Specific AIDS‐Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis | 3.7 | 56 | Citations (PDF) |
| 258 | Malignancy‐Related Deaths among HIV‐Infected Patients | 3.7 | 2 | Citations (PDF) |
| 259 | Variable Impact on Mortality of AIDS‐Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS‐Defining Conditions Are Created Equal | 3.7 | 114 | Citations (PDF) |
| 260 | The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options | 3.7 | 188 | Citations (PDF) |
| 261 | Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus | 13.1 | 93 | Citations (PDF) |
| 262 | Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies | 46.9 | 690 | Citations (PDF) |
| 263 | Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurementsAids, 2009, 23, 2199-2208 | 1.5 | 40 | Citations (PDF) |
| 264 | CD8+ Hyperactivation and Senescence Correlate With Early Carotid Intima-Media Thickness in HIV+ Patients With No Cardiovascular Disease | 1.2 | 19 | Citations (PDF) |
| 265 | Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration | 46.9 | 852 | Citations (PDF) |
| 266 | Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy | 3.7 | 7 | Citations (PDF) |
| 267 | HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignanciesAids, 2008, 22, 2143-2153 | 1.5 | 216 | Citations (PDF) |
| 268 | Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals | 2.1 | 38 | Citations (PDF) |
| 269 | Abacavir and Cardiovascular Risk in HIV‐Infected Patients: Does T Lymphocyte Hyperactivation Exert a Pathogenic Role? | 3.7 | 7 | Citations (PDF) |
| 270 | Insulin Resistance Affects Early Virologic Response in HIV-Infected Subjects Treated for Hepatitis C Infection | 1.2 | 9 | Citations (PDF) |
| 271 | Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophyAids, 2008, 22, 1769-1778 | 1.5 | 49 | Citations (PDF) |
| 272 | Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapyAids, 2008, 22, 2035-2038 | 1.5 | 263 | Citations (PDF) |
| 273 | Serum α-Fetoprotein Levels Predict Early Virologic Response in HIV-Positive Subjects Treated for Chronic Hepatitis C | 1.2 | 1 | Citations (PDF) |
| 274 | Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?Aids, 2008, 22, 2481-2492 | 1.5 | 18 | Citations (PDF) |
| 275 | Patients presenting with AIDS in the HAART era: a collaborative cohort analysisAids, 2008, 22, 2461-2469 | 1.5 | 51 | Citations (PDF) |
| 276 | Response to combination antiretroviral therapy: variation by ageAids, 2008, 22, 1463-1473 | 1.5 | 196 | Citations (PDF) |
| 277 | Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies | 1.9 | 76 | Citations (PDF) |
| 278 | Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? | 1.5 | 32 | Citations (PDF) |
| 279 | Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | 26.4 | 1,447 | Citations (PDF) |
| 280 | Is the CD4 Cell Percentage a Better Marker of Immunosuppression than the Absolute CD4 Cell Count in HIV-Infected Patients with Cirrhosis? | 3.7 | 11 | Citations (PDF) |
| 281 | Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors | 2.4 | 66 | Citations (PDF) |
| 282 | Predictive Factors of Hyperhomocysteinemia in HIV-Positive Patients | 1.2 | 12 | Citations (PDF) |
| 283 | Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesAids, 2007, 21, 1185-1197 | 1.5 | 269 | Citations (PDF) |
| 284 | Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing | 1.2 | 300 | Citations (PDF) |
| 285 | HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis | 46.9 | 214 | Citations (PDF) |
| 286 | Potential predictive factors of osteoporosis in HIV-positive subjects | 2.3 | 91 | Citations (PDF) |
| 287 | Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy | 1.2 | 44 | Citations (PDF) |
| 288 | Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe | 1.2 | 40 | Citations (PDF) |
| 289 | Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAARTAids, 2006, 20, 1727-1736 | 1.5 | 136 | Citations (PDF) |
| 290 | Treatment interruptions in HIV-infected subjects | 2.1 | 21 | Citations (PDF) |
| 291 | Subclinical hypothyroidism in HIV-infected subjects | 2.1 | 43 | Citations (PDF) |
| 292 | Reply to Boyd and Bothamley and to Franzetti et al | 3.7 | 0 | Citations (PDF) |
| 293 | Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus | 8.1 | 1,027 | Citations (PDF) |
| 294 | Long-Term Immunologic Outcome in HAART-Experienced Subjects Receiving Lopinavir/Ritonavir | 0.9 | 1 | Citations (PDF) |
| 295 | Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors | 2.4 | 64 | Citations (PDF) |
| 296 | Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir | 0.9 | 15 | Citations (PDF) |
| 297 | Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients | 0.9 | 38 | Citations (PDF) |
| 298 | Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects | 2.1 | 12 | Citations (PDF) |
| 299 | Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis | 1.9 | 40 | Citations (PDF) |
| 300 | Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison | 1.9 | 19 | Citations (PDF) |
| 301 | Osteoporosis in HIV-Infected Subjects: A Combined Effect of Highly Active Antiretroviral Therapy and HIV Itself? | 1.2 | 15 | Citations (PDF) |
| 302 | Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice | 1.2 | 47 | Citations (PDF) |
| 303 | Partnership of HIV-Infected Women and Health Status | 1.2 | 0 | Citations (PDF) |
| 304 | Impact of Coinfection With HIV-1 and GB Virus C in Patients Receiving a Ritonavir-Boosted HAART Regimen: A Substudy to the MaxCmin1 Trial | 1.2 | 6 | Citations (PDF) |
| 305 | The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy | 8.1 | 128 | Citations (PDF) |
| 306 | Effect of Hepatitis C Virus Genotype on CD4+T Cell Count in a Cohort of Antiretroviral‐Naive HIV‐1–Infected Individuals | 2.2 | 8 | Citations (PDF) |
| 307 | Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors | 2.4 | 61 | Citations (PDF) |
| 308 | Reply to Brumme and Harrigan | 2.2 | 2 | Citations (PDF) |
| 309 | Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART | 2.1 | 6 | Citations (PDF) |
| 310 | High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations | 2.4 | 52 | Citations (PDF) |
| 311 | Cutaneous B-cells non-Hodgkin's lymphoma in a HIV-infected female | 1.5 | 3 | Citations (PDF) |
| 312 | Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals | 3.7 | 46 | Citations (PDF) |
| 313 | Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America | 3.7 | 201 | Citations (PDF) |
| 314 | Economic evaluation of HIV treatments: The I.CO.N.A. cohort study | 2.0 | 13 | Citations (PDF) |
| 315 | Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals | 2.4 | 30 | Citations (PDF) |
| 316 | Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients | 1.9 | 106 | Citations (PDF) |
| 317 | Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals | 1.9 | 27 | Citations (PDF) |
| 318 | Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study | 3.7 | 121 | Citations (PDF) |
| 319 | Delayed Presentation and Late Testing for HIV: Demographic and Behavioral Risk Factors in a Multicenter Study in Italy | 1.2 | 149 | Citations (PDF) |
| 320 | Patient-reported and physician-estimated adherence to HAART | 1.5 | 60 | Citations (PDF) |
| 321 | Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects | 2.7 | 17 | Citations (PDF) |
| 322 | Changing incidence of central nervous system diseases in the EuroSIDA cohort | 4.6 | 286 | Citations (PDF) |
| 323 | Reply | 4.6 | 0 | Citations (PDF) |
| 324 | Prevalence, Associated Factors, and Prognostic Determinants of AIDS‐Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy | 3.7 | 143 | Citations (PDF) |
| 325 | Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons | 2.7 | 239 | Citations (PDF) |
| 326 | Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes | 46.9 | 309 | Citations (PDF) |
| 327 | Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure | 1.5 | 52 | Citations (PDF) |
| 328 | Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy | 1.5 | 104 | Citations (PDF) |
| 329 | Prevalence of HIV-1 Primary Drug Resistance in Seroconverters of the ICoNA Cohort Over the Period 1996???2001 | 1.2 | 19 | Citations (PDF) |
| 330 | Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems | 1.9 | 17 | Citations (PDF) |
| 331 | Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA) | 1.1 | 164 | Citations (PDF) |
| 332 | Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir | 2.4 | 6 | Citations (PDF) |
| 333 | Discontinuation of Secondary Prophylaxis forPneumocystis cariniiPneumonia in Human Immunodeficiency Virus–Infected Patients: A Randomized Trial by the CIOP Study Group | 3.7 | 41 | Citations (PDF) |
| 334 | Human Immunodeficiency Virus (HIV) DNA Load and Level of Immunosuppression in Treatment‐Naive HIV‐1–Infected Patients | 2.2 | 17 | Citations (PDF) |
| 335 | Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study | 2.1 | 6 | Citations (PDF) |
| 336 | Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex | 1.2 | 67 | Citations (PDF) |
| 337 | Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load | 1.5 | 55 | Citations (PDF) |
| 338 | Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAids, 2003, 17, 1179-1193 | 1.5 | 804 | Citations (PDF) |
| 339 | Combination Antiretroviral Therapy and the Risk of Myocardial Infarction | 26.4 | 1,599 | Citations (PDF) |
| 340 | Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimensAids, 2003, 17, 1099-1102 | 1.5 | 58 | Citations (PDF) |
| 341 | Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations | 1.9 | 21 | Citations (PDF) |
| 342 | Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes | 1.9 | 14 | Citations (PDF) |
| 343 | Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy | 1.2 | 244 | Citations (PDF) |
| 344 | Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature | 1.2 | 397 | Citations (PDF) |
| 345 | Behavioral Correlates of Adherence to Antiretroviral Therapy | 1.2 | 30 | Citations (PDF) |
| 346 | Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy | 1.2 | 56 | Citations (PDF) |
| 347 | Reply | 2.2 | 1 | Citations (PDF) |
| 348 | A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study | 2.2 | 119 | Citations (PDF) |
| 349 | Thrombotic Microangiopathy in Patients with Acquired Immunodeficiency Syndrome Before and During the Era of Introduction of Highly Active Antiretroviral Therapy | 3.7 | 82 | Citations (PDF) |
| 350 | Reduced Levels of CD4 Cell Spontaneous Apoptosis in Human Immunodeficiency Virus–Infected Patients with Discordant Response to Protease Inhibitors | 2.2 | 15 | Citations (PDF) |
| 351 | Treatment-Related Factors and Highly Active Antiretroviral Therapy Adherence | 1.2 | 67 | Citations (PDF) |
| 352 | Relationship Between HAART Adherence and Adipose Tissue Alterations | 1.2 | 159 | Citations (PDF) |
| 353 | Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimensAids, 2002, 16, 1925-1928 | 1.5 | 51 | Citations (PDF) |
| 354 | Body Habitus Changes and Metabolic Alterations in Protease Inhibitor–Naive HIV-1–Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors | 1.2 | 93 | Citations (PDF) |
| 355 | Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies | 46.9 | 1,444 | Citations (PDF) |
| 356 | Salivary stone lithotripsy in the HIV patient | 1.2 | 9 | Citations (PDF) |
| 357 | Changes in Lymphocyte Subsets in Depressed HIV-Infected Patients Without Antiretroviral Therapy | 2.7 | 10 | Citations (PDF) |
| 358 | When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study | 1.5 | 87 | Citations (PDF) |
| 359 | Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection | 1.2 | 417 | Citations (PDF) |
| 360 | Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy | 26.4 | 161 | Citations (PDF) |
| 361 | Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimensAids, 2001, 15, 1733-1736 | 1.5 | 35 | Citations (PDF) |
| 362 | Protease inhibitors and erectile dysfunctionAids, 2001, 15, 2331-2333 | 1.5 | 41 | Citations (PDF) |
| 363 | Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy | 1.9 | 5 | Citations (PDF) |
| 364 | Outcome of a Second-Line Protease Inhibitor–Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy | 1.2 | 22 | Citations (PDF) |
| 365 | Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients | 1.5 | 508 | Citations (PDF) |
| 366 | Outcome of a Second-Line Protease Inhibitor–Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy | 1.2 | 27 | Citations (PDF) |
| 367 | The Role of Lumbar Puncture in the Management of Elevated Intracranial Pressure in Patients with AIDS-Associated Cryptococcal Meningitis | 3.7 | 18 | Citations (PDF) |
| 368 | Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection | 46.9 | 209 | Citations (PDF) |
| 369 | Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS | 1.5 | 35 | Citations (PDF) |
| 370 | Influence of Age on Rates of New AIDS-defining Diseases and Survival in 6546 AIDS Patients | 1.5 | 41 | Citations (PDF) |
| 371 | High frequency of non-Hodgkinʼs lymphoma in patients with HIV-associated Kaposiʼs sarcoma | 1.5 | 22 | Citations (PDF) |
| 372 | A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients | 2.7 | 50 | Citations (PDF) |
| 373 | Atypical Mycobacterial Disease Findings at Autopsy in a Cohort of 350 AIDS Patients in Milan, Italy | 2.2 | 2 | Citations (PDF) |
| 374 | Ganciclovir Therapy for Cytomegalovirus (CMV) Infection of the Central Nervous System in AIDS Patients: Monitoring by CMV DNA Detection in Cerebrospinal Fluid | 2.2 | 49 | Citations (PDF) |
| 375 | Diagnosis of Virus-associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid | 2.6 | 3 | Citations (PDF) |
| 376 | Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions | 1.5 | 57 | Citations (PDF) |
| 377 | Foscarnet treatment of chronic hepatitis B in an HIV-positive patient | 6.7 | 5 | Citations (PDF) |
| 378 | Factors Associated with Increased Risk of Acquiring Cytomegalovirus Disease in AIDS Patients | 2.2 | 16 | Citations (PDF) |
| 379 | Reply | 2.2 | 1 | Citations (PDF) |
| 380 | Mother-to-Child Transmission of Hepatitis C Virus Detected by Nested Polymerase Chain Reaction | 2.2 | 165 | Citations (PDF) |
| 381 | AIDS-defining diseases in 250 HIV-infected patients; a comparative study of clinical and autopsy diagnoses | 1.5 | 58 | Citations (PDF) |
| 382 | T-cell subsets and serum immunoglobulin levels in infants born to HIV-seropositive mothers | 1.5 | 9 | Citations (PDF) |
| 383 | Early diagnosis of HIV infection in infants | 1.5 | 6 | Citations (PDF) |
| 384 | Hepatitis B Virus-Associated Coinfection and Superinfection with Agent: Indistinguishable Disease with Different Outcome | 2.2 | 88 | Citations (PDF) |
| 385 | An Outbreak of Delta Agent among a Group of Drug Addicts and Their Close Contacts | 2.2 | 19 | Citations (PDF) |
| 386 | PERSISTENCE OF CIRCULATING HBsAg/IgM COMPLEXES IN ACUTE VIRAL HEPATITIS, TYPE B: AN EARLY MARKER OF CHRONIC EVOLUTION | 46.9 | 35 | Citations (PDF) |
| 387 | Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART | 2.1 | 9 | Citations (PDF) |
| 388 | Title is missing! 0 | | 2 | Citations (PDF) |
| 389 | Title is missing! 0 | | 1 | Citations (PDF) |
| 390 | Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy | 0.3 | 3 | Citations (PDF) |
